PCO: Novel Technique of Pneumatic Posterior Capsulorhexis for Treatment and Prevention of Posterior Capsular Opacification

Sponsor
Minia University (Other)
Overall Status
Completed
CT.gov ID
NCT04007965
Collaborator
(none)
100
1
2
29.7
3.4

Study Details

Study Description

Brief Summary

ABSTRACT PURPOSE: To evaluate a new technique of posterior capsulorhexis using air support to treat primary posterior capsular opacification (PCO) during cataract extraction surgery or to prevent post-operative PCO.

SETTING: 1-Ophthalmology department, Faculty of medicine, Minia University, El-Minia, Egypt.

2- Security Forces Hospital, Ophthalmology Department, Riyadh, Kingdom of Saudi Arabia.

DESIGN: Prospective, randomized case-control comparative study.

Methods: 100 eyes of 100 patients with a mean age of 63.3 years with dens cataract. Fifty of them ( group 1) with primary PCO (discovered during the operations) and fifty (group 2) with clear posterior capsule.

All cases undergone phacoemulsification, posterior capsulorhexis using the air to support the posterior capsule and separate it from the vitreous (the novel technique will be discussed later). Then IOL implantations wear done in the bag between the anterior and posterior capsular rim. Each patient was evaluated for the following:- visual acuity (UCVA and BCVA), intraocular pressure, intra ocular lens stability, visual axis opacification and posterior segment complications as retinal break, retinal detachment or cystoid macular oedema.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pneumatic Posterior Capsulorhexis
N/A

Detailed Description

Introduction. Posterior capsular opacification (PCO) is one of the common late post-operative complications of phacoemulsification and ECCE. The treatment of PCO by YAG laser capsulotomy usually leads to the famous annoying symptom (musca) and carries the risk of IOP elevation. Moreover, it may lead to the posterior segment complications ( cystoid macular edema, retinal breaks and detachment). There is no reliable treatment for prevention of PCO.

The current available modalities to prevent postoperative PCO are:
  • Some surgical modifications as hydrodissection, repeated nucleus rotation and meticulous polishing of the lens epithelial cells (LECs) from anterior capsular rim and equator. In 1989 David Apple and his group (1) had demonstrated the value of hydrodissection. In 1992, they further emphasized hydrodissection as well as barriers to migration of equatorial cells to the posterior capsule as methods which could reduce PCO (2). In the same year Fine described a technique which he termed 'cortical cleaving hydrodissection', (3) which was designed to break the equatorial adhesions between lens epithelial cells and the capsule, thus increasing the chance of significant clearance of these cells which are the progenitors of PCO. In 2006 they pointed out to the laboratory and clinical evidence that good hydrodissection, coupled with mechanical 'scouring' of LECs from the equator may have beneficial effect on decreasing PCO incidence. (4,5). In a laboratory experiment they found that there were significantly fewer cells remaining in the capsule equator in the group of eyes where the lens had been rotated three times within the bag prior to removal, compared with no such rotation(4).

  • Changes in the IOL design and materials: e.g. The square edge of the optic and acrylic IOL decreases the incidence of postoperative PCO than with PMMA IOLs of similar design.

  • Pharmacological strategies either to kill the residual epithelial cells or to prevent their post operative proliferation. The pharmacological prevention has been largely unsuccessful so far. Moreover, any agent must be toxic to these epithelial cells without being toxic to the corneal endothelium. Few agents have been partially successful without clinical application till now (6).

The incidence of PCO following successful cataract surgery has been falling since the general acceptance of posterior chamber in-the-bag intraocular lens (IOL) implantation. Improvement in lens materials, lens design and technique are well documented to decrease the incidence of postoperative PCO (8, 9). Rotation three times of the hydrodissected nucleus prior to phacoemulsification and a second hydrodissection after nucleus removal are simple and safe maneuvers that statistically improve the results (9). Bimanual irrigation/aspiration may also help.(10) Treatment options for PCO

  • YAG laser posterior capsulotomy

  • Surgical posterior capsulotomy or capsulectomy

  • Primary (Intra-operative)

  • Secondary.

Patients and methods:

Indications of the new technique

  1. Intraoperative PCO in white cataract.

  2. As a primary procedure during cataract extraction to prevent post-operative PCO. Thirty eyes of 100 patients with dens cataract were chosen from the outpatient clinic of the ophthalmology department, Minia University Hospital, El-Minia Egypt. The patient's age ranged from 50-73 years with a mean age of 63.3 years 50 males and 50 females without any local or systemic causes for the cataract. The study group included fifty eyes (group1) with PCO, and fifty eyes (group 2) with clear posterior capsule (discovered intra-operative). All cases were subjected to complete ophthalmic examinations and echographic data registration. All cases undergone Phacoemulsification, posterior capsulorhexis using the air to support the posterior capsule and separate it from the vitreous face. Table (1)

The novel technique:
After complete phacoemulsification of the nucleus and I/A:
  1. Visco-elastic material was injected to make the anterior chamber formed without deepening so that the posterior capsule is not forcibly pushed backward.

  2. The posterior capsule punctured centrally using cysteotome Fig. (1).

  3. Controllable one shot injection of 0.1 ml of sterile air through the posterior capsule puncture which elevate, support and separate the posterior capsule from vitreous face. (Insulin syringe and Helon cannula were used) Fig. (2).

  4. Another visco-elastic injection to the anterior chamber to stretch the posterior capsule and sandwitich it between visco-elastic above and the air below Fig. (3).

  5. Posterior capsulorhexis 4-5 mm is now performed easily using capsulorhexis forceps then foldable IOL was implanted between the anterior and posterior capsular rim .

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Novel Technique of Pneumatic Posterior Capsulorhexis for Treatment and Prevention of Posterior Capsular Opacification
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Jan 31, 2018
Actual Study Completion Date :
Jun 25, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Opacified posterior capsule

PCO

Procedure: Pneumatic Posterior Capsulorhexis
Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.

Active Comparator: Clear posterior capsule

CPC

Procedure: Pneumatic Posterior Capsulorhexis
Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.

Outcome Measures

Primary Outcome Measures

  1. Visual acuity measured using snellen chart projector [one year]

    visual acuity (UCVA and BCVA) measured in decimal values

  2. IOP measured in numerical values [one year]

    Intra-ocular pressure measured by Tono pen

  3. IOL stability [one year]

    Intraocular Lens stability seen by slit lamb examination

  4. Visual Axis Opacification [0ne year]

    Visual Axis Opacification seen by slit lamb examination

Secondary Outcome Measures

  1. posterior segment complications [18 months]

    posterior segment complications as retinal break, retinal detachment or cystoid macular oedema.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 73 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Dense mature cataract without any local or systemic causes for the cataract.
Exclusion Criteria:
  • Any patients did not complete the follow up visits

  • younger patients and children

Contacts and Locations

Locations

Site City State Country Postal Code
1 Security forces hospital Riyadh Central Saudi Arabia 11481-3643

Sponsors and Collaborators

  • Minia University

Investigators

  • Study Chair: Ahmed M Eid, MD, Minia University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Shaaban Elwan, Assistant professor of ophthalmology, Minia University
ClinicalTrials.gov Identifier:
NCT04007965
Other Study ID Numbers:
  • Minia University
First Posted:
Jul 5, 2019
Last Update Posted:
Jul 5, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shaaban Elwan, Assistant professor of ophthalmology, Minia University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2019